Klaus Fütterer

Klaus Fütterer

Auto-generated profile, based on publicly available information

Klaus Fütterer

School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, England

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 1999 in Science
Verified
Journal Article
Closed access
PDF file
FSFrederic G. Sauer
Frederic G. Sauer
KFKlaus FütTerer
Klaus FütTerer
JPJerome S. Pinkner
Jerome S. Pinkner
KDKaren W. Dodson
Karen W. Dodson
SHScott J. Hultgren
Scott J. Hultgren
GWGabriel Waksman
Gabriel Waksman
Many Gram-negative pathogens assemble architecturally and functionally diverse adhesive pili on their surfaces by the chaperone-usher pathway. Immunoglobulin-like periplasmic chaperones escort pilus subunits to the usher, a large protein complex that facilitates the translocation and assembly of subunits across the outer membrane. The crystal structure of the PapD-PapK chaperone-subunit complex, determined at 2.4 angstrom resolution, reveals that the chaperone functions by donating its G 1 β strand to complete the immunoglobulin-like fold of the subunit via a mechanism termed donor strand complementation. The structure of the PapD-PapK complex also suggests that during pilus biogenesis, every subunit completes the immunoglobulin-like fold of its neighboring subunit via a mechanism termed donor strand exchange.

6 January 2005 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TMThomas H Millard
Thomas H Millard
GBGuillaume Bompard
Guillaume Bompard
MHMan Yeung Heung
Man Yeung Heung
TDTimothy R Dafforn
Timothy R Dafforn
DSDavid Scott
David Scott
KFKlaus Fütterer
Klaus Fütterer
The scaffolding protein insulin receptor tyrosine kinase substrate p53 (IRSp53), a ubiquitous regulator of the actin cytoskeleton, mediates filopodia formation under the control of Rho‐family GTPases. IRSp53 comprises a central SH3 domain, which binds to proline‐rich regions of a wide range of actin regulators, and a conserved N‐terminal IRSp53/MIM homology domain (IMD) that harbours F‐actin‐bundling activity. Here, we present the crystal structure of this novel actin‐bundling domain revealing a coiled‐coil domain that self‐associates into a 180 Å‐long zeppelin‐shaped dimer. Sedimentation velocity experiments confirm the presence of a single molecular species of twice the molecular weight of the monomer in solution. Mutagenesis of conserved basic residues at the extreme ends of the dimer abrogated actin bundling in vitro and filopodia formation in vivo , demonstrating that IMD‐mediated actin bundling is required for IRSp53‐induced filopodia formation. This study promotes an expanded view of IRSp53 as an actin regulator that integrates scaffolding and effector functions.

28 September 2003 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
GMGuoyu Meng
Guoyu Meng
KFKlaus Fütterer
Klaus Fütterer

25 June 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SBSarah M. Batt
Sarah M. Batt
TJTalat Jabeen
Talat Jabeen
VBVeemal Bhowruth
Veemal Bhowruth
LQLee Quill
Lee Quill
PLPeter A. Lund
Peter A. Lund
GBGurdyal S. Besra
Gurdyal S. Besra
Resistance against currently used antitubercular therapeutics increasingly undermines efforts to contain the worldwide tuberculosis (TB) epidemic. Recently, benzothiazinone (BTZ) inhibitors have shown nanomolar potency against both drug-susceptible and multidrug-resistant strains of the tubercle bacillus. However, their proposed mode of action is lacking structural evidence. We report here the crystal structure of the BTZ target, FAD-containing oxidoreductase Mycobacterium tuberculosis DprE1, which is essential for viability. Different crystal forms of ligand-free DprE1 reveal considerable levels of structural flexibility of two surface loops that seem to govern accessibility of the active site. Structures of complexes with the BTZ-derived nitroso derivative CT325 reveal the mode of inhibitor binding, which includes a covalent link to conserved Cys387, and reveal a trifluoromethyl group as a second key determinant of interaction with the enzyme. Surprisingly, we find that a noncovalent complex was formed between DprE1 and CT319, which is structurally identical to CT325 except for an inert nitro group replacing the reactive nitroso group. This demonstrates that binding of BTZ-class inhibitors to DprE1 is not strictly dependent on formation of the covalent link to Cys387. On the basis of the structural and activity data, we propose that the complex of DrpE1 bound to CT325 is a representative of the BTZ-target complex. These results mark a significant step forward in the characterization of a key TB drug target.

1 August 1998 in Journal of Molecular Biology
Verified
Journal Article
Closed access
KFKlaus Fütterer
Klaus Fütterer
JWJane Wong
Jane Wong
RGRichard Grucza
Richard Grucza
ACAndrew C. Chan
Andrew C. Chan
GWGabriel Waksman
Gabriel Waksman

17 June 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
FWFeng Wang
Feng Wang
DSDhinakaran Sambandan
Dhinakaran Sambandan
RHRajkumar Halder
Rajkumar Halder
JWJianing Wang
Jianing Wang
SBSarah M. Batt
Sarah M. Batt
PSPeter G. Schultz
Peter G. Schultz
Significance: The global problem of TB has worsened in recent years with the emergence of drug-resistant organisms, and new drugs are clearly needed. In a cell-based high-throughput screen, a small molecule, TCA1, was discovered that has activity against replicating and nonreplicating Mycobacterium tuberculosis . It is also efficacious in acute and chronic rodent models of TB alone or combined with frontline TB drugs. TCA1 functions by a unique mechanism, inhibiting enzymes involved in cell wall and molybdenum cofactor biosynthesis. This discovery represents a significant advance in the search for new agents to treat persistent and drug-resistant TB.